Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are commonly used to treat type 2 diabetes mellitus (T2D), but their effects on gastric mortality can lead to residual gastric contents that interfere with esophagogastroduodenoscopies [1, 2]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.